期刊文献+

核苷类抗病毒药群体药动学研究及应用 被引量:1

Study and Application of Antiviral Nucleoside Population Pharmacokinetic
下载PDF
导出
摘要 群体药动学运用经典药动学统计学相结合的方法来定量考察目标群体中药物浓度的影响因素,并应用于优化临床药物治疗方案。核苷类抗病毒药在临床抗病毒治疗中发挥重要的作用,此类药物的疗效、不良反应与其体内药物浓度息息相关,阿昔洛韦、更昔洛韦、泛昔洛韦、齐多夫定、恩曲他滨、拉米夫定和阿巴卡韦等核苷类抗病毒药的群体药动学研究促进该类药物在临床的合理应用。 Population pharmacokinetics use Pharmacokinetics classic combination of statistical methods to quanti -fy the factor influencing the drug concentration in the target groups ,and can be applied to optimize the clinical drug treatment programs through the use of statistical methods .Nucleoside antiviral drugs play an important role in the clinical antiviral therapy ,the efficacy of these drugs ,adverse drug reactions and its concentration in the body is close-ly related to,the population pharmacokinetic study of acyclovir ,ganciclovir,famciclovir,zidovudine,emtricitabine, lamivudine and abacavir promote rational use of these drugs in the clinic .
出处 《海峡药学》 2016年第7期4-7,共4页 Strait Pharmaceutical Journal
关键词 群体药动学(PPK) 非线性混合效应模型(NONMEM) 核苷类抗病毒药 Population pharmaeokinetic (PPK) nonlinear mixed effects model (NONMEM) nucleoside antiviral drug
  • 相关文献

参考文献19

  • 1林玮玮,王长连.群体药物代谢动力学原理及应用进展[J].医学综述,2008,14(9):1394-1397. 被引量:4
  • 2苏汉中,张善堂,陈卫东,唐丽琴,童彤,邱蕾.群体药动学及其应用研究进展[J].安徽医药,2015,19(2):205-209. 被引量:11
  • 3林翠鸿,王长连,柯蒙.群体药动学及其在个体化给药中的应用[J].中国临床药学杂志,2005,14(1):58-60. 被引量:8
  • 4张弨,赵荣生,翟所迪,单爱莲.群体药代动力学概述[J].中国临床药理学杂志,2013,29(8):563-565. 被引量:15
  • 5James P.Smith,Stephen Weller,Benjamin Johnson,et al.Pharmacokinetics of acyclovir and systemic circulation after administration of high-dose valacyclovir in subjects with normal and impaired renal function[J].Antimicrobial Agents and Chemotherapy,2010,54(3):1146-1151.
  • 6Zeng.L,Nath.C.E,Blair.E.Y.L,et al.Population pharmacokinetics of acyclovir in children and young people with malignancy after administration of intravenous acyclovir or oral valacyclovir[J].Antimicrobial Agents and Chemotherapy,2009,53(7):2918-2927.
  • 7MarioR.Sampson,Barry T.Bloom,Robert W.Lenfestey,et al.Population pharmacokinetics of intravenous acyclovir in preterm and term infants[J].The Pediatric infectious Disease Journal,2014,33(1):42-49.
  • 8Perrottet.N,Csajka.C,Pascual.M,et al.Population pharmacokinetics of ganciclovir in solid-organ transplant recipients receiving oral valganciclovir[J].Antimicrobial Agents and Chemotherapy,2009,53(7):3017-3023.
  • 9Calds.A,Colom.H,Armendariz.Y,et al.Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients Infected with cytomegalovirus[J].Antimicrobial Agents and Chemotherapy,2009,53(11):4816-4824.
  • 10Acosta.EP,Brandage.RC,King.JR,et al.Ganciclovir population pharmacokinetics in neonates following intsavenous administration of a liquid valganciclovir formulation[J].Clinical Pharmacology&Therapeutic,2007,81(6):867-872.

二级参考文献61

  • 1李珍,陈刚.住院病人茶碱群体药物动力学NONMEM法分析[J].中国药理学报,1994,15(3):267-270. 被引量:6
  • 2芮建中,杨友春.王亦流,陈刚.硫酸镁治疗妊娠高血压综合征的群体药动学一药效学[J].药学学报,1996,31(2):81-85. 被引量:3
  • 3Charles M,Thomas S.Expanding clinical applications of population pharmacokinetics modeling[J].Br J Pharmacol,1998,46(4):321.
  • 4Roger J, Alan S, Michael VG. Population pharmacokinetics/pharmacodynamics modeling: parametric and nonparametric methods [J]. Ther Rrug Monit, 2000,22(3) :354.
  • 5Sheiner LB, Rosenberg B, Marathe VV. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data [J]. J Pharmacokinet Biopharm, 1977,5 (5) : 445.
  • 6Vozeh S, Steimer JL, Rowland M, et al. The use of population pharmacokinetics in drug development[ J]. Clin Pharmacokinet, 1996,30(2) : 81.
  • 7Triggs EJ, Charles BG, Contin M, et al. Population pharmacokinetics and pharmacodynamics of oral levodopa in parkinsonian patients [J].Eur J Clin Pharmacol, 1996,51(1) :59.
  • 8Annick R, Pierre M. Application of pharmacokinetic modeling to the routine therapeutic drug monitoring of anticancer drugs[J]. Fundam Clin Pharmacol, 2002.16(4) :253.
  • 9Willams PJ, Ette EI. The role of population pharmaeokineties in drug development in light of the Food and Drug Administration's Guidance for Industry: population pharmacokinetics [J]. Clin Pharmacokinet ,2000,39 ( 6 ) :385-395.
  • 10Ouellet D, Bockbrader HN, Wesche DL,et al. Population phamlacokinetics of gababentin in infants and children [ J ]. Epilepsy Res,2001,47 (3) :229-241.

共引文献32

同被引文献5

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部